One page per substance
Grouped the way people search for them.
What's inside
Every page answers the same questions, in the same order.
Pick any substance and you get the same fourteen sections, so comparing two compounds takes seconds.
FDA status, stated plainly
Approval, compounding and enforcement are tracked separately on every page.
- FDA approved 19
- FDA cleared (device) 1
- In clinical trials 4
- Not approved 34
Doses reported in trials
Exactly as each study reported them, with the population and schedule. Not personal dosing instructions.
| Trial | Phase | Dose as reported |
|---|---|---|
| STEP 1 | 3 | 2.4 mg subcutaneous once weekly, titrated from 0.25 mg over 16 weeks, 68 weeks total |
| SELECT | 3 | 2.4 mg subcutaneous once weekly |
| FLOW | 3 | 1.0 mg subcutaneous once weekly |
Plain English or Scientific
Semaglutide is a lab-made copy of GLP-1, a gut hormone released after meals. It was engineered to last about a week, so it is a once-weekly injection.
Semaglutide is a GLP-1(7-37) analogue with an Aib8 substitution for DPP-4 resistance and a C18 diacid on Lys26 for albumin binding, giving a half-life of about 165 hours.
Every page covers
- Names & brands
- Molecule & sequence
- Who made it
- Doses reported in trials
- Results so far
- FDA approval
- Compounding status
- Enforcement history
- Side effects
- Interactions
- Contraindications
- Storage
- Patents
- References
Sourced, then checked
497
primary references: FDA labels, ClinicalTrials.gov records, PubMed papers and regulator notices. Each page shows when its sources were last checked.
Good places to start
Six pages to start with.
approved Semaglutide A GLP-1 receptor agonist (weekly injection or daily tablet), approved for type 2 diabetes, chronic weight management, cardiovascular and kidney risk reduction, and MASH. approved Tirzepatide A once-weekly dual GIP and GLP-1 receptor agonist, approved for type 2 diabetes (adults and children 10 and older), cardiovascular risk reduction in type 2 diabetes, chronic weight management and obstructive sleep apnoea. investigational Retatrutide An investigational once-weekly triple agonist of the GIP, GLP-1 and glucagon receptors from Eli Lilly, with Phase 3 obesity results reported in 2025–2026. Not approved anywhere. none BPC-157 A synthetic 15-amino-acid fragment of a gastric juice protein, studied almost entirely in rodents; not FDA approved, placed in 503A Category 2 in 2023, withdrawn from that category in 2026 and now under advisory-committee review. none TB-500 (thymosin β4 fragment) A synthetic 7-amino-acid piece of the natural protein thymosin β4; the clinical trials belong to full-length thymosin β4, not to TB-500, which has no genuine human trial of its own and no approval anywhere. approved OnabotulinumtoxinA The botulinum toxin type A product approved in the United States as Botox and Botox Cosmetic, with potency Units specific to this preparation and a boxed warning for distant spread of toxin effect.
Site assistant · Reporting for duty soon
Meet Sergeant Pep.
Sgt. Pep is being built to answer questions from the pages on this site: what a trial found, what phase a compound is in, what a term means. Every answer will link to the page it came from.
Questions he is built for
- What phase is retatrutide in?
- What did the SELECT trial find?
- Is BPC-157 FDA approved?
- What does 503A Category 2 mean?
He is software, not a professional. He will not give personal medical advice or say where to buy anything.
Meet Sgt. Pep